Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial

Robert Bissonnette; Lars Iversen; Howard Sofen; Christopher Em Griffiths; Peter Foley; Ricardo Romiti; Mary Bachinsky; Scott T. Rottinghaus; Hsiewe Ying Tan; James Proulx; H. Valdez; Pankaj Gupta; Lotus Mallbris; Robert Wołk

Related publications

Article2014

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Robert Bissonnette, Lars Iversen, Howard Sofen, Christopher Em Griffiths, Peter Foley, Ricardo Romiti, Mary Bachinsky, S.T. Rottinghaus, Huaming Tan, James Proulx, Hernán Valdez, Pankaj Gupta, Lotus Mallbris, Robert Wołk

Article2016

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Christopher Em Griffiths, Ronald Vender, Howard Sofen, Leon Kircik, Huaming Tan, Scott T. Rottinghaus, Mary Bachinsky, Lotus Mallbris, Carla Mamolo

Article2005

Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial

Alice B. Gottlieb, Christopher Em Griffiths, Vincent Ho, M. Lahfa, Ulrich Mrowietz, Dédée F. Murrell, Ortonne Jp, Gail Todd, Robert Cherill, I. N. Marks, Shahram Emady‐Azar, C. Paul

Article2016

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

Huaming Tan, Hernán Valdez, Christopher Em Griffiths, Ulrich Mrowietz, Anna M. Tallman, Robert Wołk, Kenneth B. Gordon

Article2003

An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis

Mark Lebwohl, Enno Christophers, Richard G. Langley, Jean Paul Ortonne, Janet L. Roberts, Christopher Em Griffiths